Tango Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 21.91 USD (Oct 30, 2026, 3:18 PM EDT) · Market cap 3.69B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Details
| Name | Tango Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 137 |
| Founded | 2014 |
| Ceo | Malte Peters |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US87583X1090 |
| Cusip | 87583X109 |
| Cik | 1819133 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Malte Peters M.D. | President, Chief Executive Officer and Director |
| Dr. Barbara L. Weber M.D. | Executive Officer |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research and Development |
| Prof. Alan Ashworth FRS, Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. William G. Kaelin Jr., M.D. | Founder and Member of Scientific Advisory Board |
| Dr. Antoni Ribas M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Matthew Gall M.B.A. | Chief Financial Officer |
| Jannik N. Andersen Ph.D. | Chief Scientific Officer |
| Elizabeth Pingpank Hickin | Vice President of IR and Corporate Communications |
| Julie Fogarty | Senior Vice President, General Counsel and Corporate Secretary |
Contact
| Address | 201 Brookline Avenue, Suite 901, Boston, Massachusetts 02215, United States |
| Phone | 857 320 4900 |
| Website | https://www.tangotx.com |